*Disclaimer

PHARMAUST LIMITED (ASX: PAA)

🔗 📄 📈

PAA: Results show MPL suppresses biomarkers associated with MND

PHARMAUST LIMITED

2023-07-11 10:27:00

PAA: MND Biomarkers and Pharmacodynamics Results

PHARMAUST LIMITED

2023-07-04 09:50:00

PAA: Motor Neurone Disease Phase 1/2 Clinical Trial Update

PHARMAUST LIMITED

2023-06-27 08:17:00

PAA: PharmAust MND Trial Interim Analysis PK Outcomes

PHARMAUST LIMITED

2023-06-07 09:31:00

PAA: Motor Neurone Disease Clinical Trial Update

PHARMAUST LIMITED

2023-05-22 09:29:00

PAA: Progress update on Phase 1/2 MND interim analysis

PHARMAUST LIMITED

2023-05-16 08:27:00

PAA: Independent tests show MPL retains long-term shelf-life

PHARMAUST LIMITED

2023-05-10 08:19:00

PAA: MPL has anti-cancer effects across multiple cancer types

PHARMAUST LIMITED

2023-05-09 08:17:00

PAA: PharmAust Raises $2.5m via Placement

PHARMAUST LIMITED

2023-05-03 10:09:00

PAA: MND Trial Successfully Completes Second Patient Cohort

PHARMAUST LIMITED

2023-04-28 08:34:00

PAA: Canine Trial Update

PHARMAUST LIMITED

2023-04-21 08:18:00

PAA: Arrival of additional MPL tablets

PHARMAUST LIMITED

2023-04-17 08:27:00

PAA: PharmAust launches international CEO search

PHARMAUST LIMITED

2023-04-13 08:22:00

PAA: MND Trial Completes Enrolment of Cohort 2

PHARMAUST LIMITED

2023-03-30 09:17:00

PAA: Stable Patient in MND trial reaches 6-months on MPL

PHARMAUST LIMITED

2023-03-28 09:21:00

PAA: Canine Cancer Trial Update

PHARMAUST LIMITED

2023-03-07 08:19:00

PAA: Interim analysis recommended in MND trial

PHARMAUST LIMITED

2023-03-02 08:14:00

PAA: European Patent relating to MPL Combinations in Cancer

PHARMAUST LIMITED

2023-02-28 07:57:00

PAA: First Patient of Cohort 2 Dosed in MND Trial

PHARMAUST LIMITED

2023-02-20 08:03:00

PAA: PharmAust Progresses to Elevated Doses in MND Patients

PHARMAUST LIMITED

2023-01-20 08:22:00

PAA: MND Trial Successfully Completes First Patient Cohort

PHARMAUST LIMITED

  1. Monepantel (MPL) was well tolerated by all MND patients at the first dosing level
  2. All six patients in cohort 1 have elected to continue on MPL treatment
  3. Safety and efficacy data from the trial will also be used to facilitate a Phase 2 study in COVID-19 patients

2023-01-06 09:09:00